Impure but not inactive: Behavioral pharmacology of dibenzylpiperazine, a common by-product of benzylpiperazine synthesis.

Sean B DolanRitu A ShettyMichael J ForsterMichael B Gatch

Published in: Journal of psychopharmacology (Oxford, England) (2018)

These data indicate that DBZP is more similar to BZP, albeit with lower potency and efficacy, than its serotonergic piperazine counterparts, and is a behaviorally-active compound with some abuse liability and potential for adverse health effects.

Keyphrases

electronic health record
big data
human health
emergency department
adverse drug
machine learning
artificial intelligence
climate change